Nebius Group NV vs uniQure N.V. Ordinary Shares — how do they compare? Nebius Group NV trades at $180.04 (market cap $56.24B), while uniQure N.V. Ordinary Shares trades at $20.78 (market cap $1.48B). The key difference: Nebius Group NV is far larger — about 38× uniQure N.V. Ordinary Shares's market cap, and Nebius Group NV is trading nearer its 52-week high, uniQure N.V. Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nebius Group NV for 25 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| NBIS | QURE | |
|---|---|---|
Market Cap | $56.24B | $1.48B |
Volume | 17,483,721 | 2,488,780 |
Sector | Technology | Health |
52-Week High | $286.69 | $70.59 |
52-Week Low | $73.87 | $9.03 |
Typical Hold Time | 25 Days | 0 Days |
Enterprise Value | $58.36B | $728.62M |
Signals from Pluang's Aura AI — not financial advice
NBIS trades at $206.86, down 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows high valuation ratios (P/E 795.62, P/S 42.26) against modest profitability (net margin 3.13%, ROE 0.6%). Recent news highlights AI infrastructure growth potential but also insider selling and competitive risks.
Analyst consensus remains bullish with 82% buy ratings and a $288.67 price target, suggesting 40% upside. Key risks include high capital expenditure, negative cash flow from investing, and dependence on AI demand sustainability. The stock's outlook hinges on execution of its $37B backlog and GPU rental pricing trends.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Nebius Group N.V. is a technology company specializing in AI, machine learning, and cloud computing solutions. The company provides a range of enterprise-level cloud services, including large-scale data processing, advanced analytics, and AI model development and deployment. Nebius Group focuses on serving businesses that require high-performance, scalable, and secure infrastructure to handle complex computational tasks and accelerate their digital transformation.
Read more on NBIS →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →